Stock Comparison

INCY vs JNJ

Incyte Corp vs Johnson & Johnson

The Verdict

JNJ takes this one.

INCY

Incyte Corp

0.6

out of 10

Distressed

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$20.8B

Market Cap

$557.1B

14.5

P/E Ratio

26.5

26.7%

Profit Margin

21.8%

29.2%

Return on Equity

26.3%

0.0

Debt-to-Equity

0.6

Moderate

Overall Risk

Conservative

0.6

DVR Score

1.0

The Deep Dive

INCY0.6/10

Incyte (INCY) is a well-established large-cap biopharmaceutical company ($20.45B market cap) showing solid Q1 2026 performance with an 85.4% YoY EPS beat and positive pipeline updates for zilurgisertib and Opzelura. These factors suggest continued steady growth and operational strength. However, consistent with previous analysis, its current size and operational maturity in the biopharmaceutical s...

Full INCY Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.